Cargando…
Favorable outcomes with reduced steroid use in juvenile dermatomyositis
BACKGROUND: High-intensity glucocorticoid regimens are commonly used to induce and maintain remission in Juvenile Dermatomyositis but are associated with several adverse side-effects. Evidence-based treatment guidelines from North American and European pediatric rheumatology research societies both...
Autores principales: | Orandi, Amir B., Fotis, Lampros, Lai, Jamie, Morris, Hallie, White, Andrew J., French, Anthony R., Baszis, Kevin W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369654/ https://www.ncbi.nlm.nih.gov/pubmed/34404425 http://dx.doi.org/10.1186/s12969-021-00615-0 |
Ejemplares similares
-
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
por: Orandi, Amir B., et al.
Publicado: (2018) -
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
por: Orandi, A. B., et al.
Publicado: (2017) -
Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases
por: Fotis, Lampros, et al.
Publicado: (2016) -
Juvenile Dermatomyositis in Pregnancy
por: Madu, Anthony Emeka, et al.
Publicado: (2013) -
Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)